drugset / Trial / NCT06359535

An Economic Study of HSK21542 Injection for Prevention of Postoperative Nausea and Vomiting

NCT06359535

Phase 4 Unknown 200 enrolled Mengchang Yang
RandomizedParallel-groupOpen-labelOther

Summary

This study analyzed the efficacy and safety results of HSK21542 injection for the prevention of postoperative nausea and vomiting in a multicentre, randomized, double-blind, placebo-controlled dose-exploration study, as well as the real-world clinical routine use of troisisone and other (not limited to other setron drugs) for the prevention of postoperative nausea and vomiting and related adverse reaction treatment data. It was transformed into an effect indicator, and the possible costs involved in the study were analyzed, reasonable price parameters of HSK21542 injection were set, and the economic value of HSK21542 was explored.

Timeline

Start
2024-02-23
Primary completion
2024-11-06
Completion
2024-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK21542 Peptide 60 ug Intravenous
Subject HSK21542 Peptide 120 ug Intravenous
Subject HSK21542 Peptide 180 ug Intravenous

Indications

No indication recorded.